Related Experiment Video

Updated: Aug 7, 2026

In vivo Imaging of Transgenic Leishmania Parasites in a Live Host
09:53

In vivo Imaging of Transgenic Leishmania Parasites in a Live Host

Published on: July 27, 2010

Immunology of canine leishmaniasis

C L Barbiéri1

  • 1Division of Parasitology, Department of Immunology, Microbiology and Parasitology, Universidade Federal de São Paulo, Escola Paulista de Medicina, São Paulo, SP, Brazil. barbiericl@ecb.epm.br

Parasite Immunology
|July 18, 2006
PubMed

Insights

Dogs are key reservoirs for visceral leishmaniasis (VL). Immune responses, particularly Th1-mediated cellular immunity, are crucial for resistance in dogs, guiding vaccine development to control human VL.

Area of Science:

  • Veterinary Immunology
  • Parasitology
  • Infectious Diseases

Background:

  • Dogs serve as the primary reservoir for visceral leishmaniasis (VL), a zoonotic disease with significant public health implications.
  • Understanding canine immune responses is critical for controlling human VL transmission.

Purpose of the Study:

  • To review immune responses in canine visceral leishmaniasis (CVL).
  • To identify Leishmania antigens involved in protective immunity.
  • To discuss strategies for developing an effective CVL vaccine.

Main Methods:

  • Review of existing literature on canine immune responses to Leishmania infection.
  • Analysis of cellular and cytokine profiles associated with resistance and susceptibility.
  • Identification of key Leishmania antigens.

Main Results:

  • Asymptomatic dogs show resistance, characterized by Th1-subset immune responses (IFN-gamma, TNF-alpha).
  • Th2 cytokines (IL-4, IL-10) are increasingly correlated with progressive disease, though their role is debated.
  • CD8+ cytotoxic T cells may also contribute to resistance.

Conclusions:

  • Immune responses, particularly Th1-driven cellular immunity, are central to canine resistance against visceral leishmaniasis.
  • Identifying protective Leishmania antigens is key for vaccine development.
  • Vaccine strategies targeting canine immunity could reduce human VL prevalence.

More Related Videos

Cutaneous Leishmaniasis in the Dorsal Skin of Hamsters: a Useful Model for the Screening of Antileishmanial Drugs11:36

Cutaneous Leishmaniasis in the Dorsal Skin of Hamsters: a Useful Model for the Screening of Antileishmanial Drugs

Published on: April 21, 2012

Related Concept Videos

Leishmaniasis01:30

Leishmaniasis

Leishmaniasis is a protozoal disease caused by species of the genus Leishmania and transmitted through the bite of infected female sandflies. The parasite exists in two principal morphological forms during its life cycle. A sandfly acquires intracellular amastigotes from an infected reservoir host, such as a dog. Within the sandfly, these forms differentiate into motile, flagellated promastigotes. During a subsequent blood meal, promastigotes are injected into the human host, where they...
Antiprotozoal Agents01:21

Antiprotozoal Agents

Leishmaniasis is a widespread parasitic disease caused by several Leishmania species. It affects millions of people each year and remains a major public health problem in endemic regions. First-line treatment relies on pentavalent antimonials, including meglumine antimoniate and sodium stibogluconate. Even so, how these drugs work has not been fully clear, especially their interaction with parasite-specific biochemical pathways. One key target is trypanothione reductase (TR), an enzyme that...